Feed CYBN
CY

Cybin Inc.

CYBN · AMEX

$8.28 +1.22% (+$0.10)
Piotroski F-Score Weak
0/9
Valuation
-
N/A
PEG N/A
P/E N/A
P/FFO N/A
Growth
-
N/A
FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
-
N/A
ROA N/A
ROIC N/A
Asset turnover N/A
Debt
-
N/A
Int. coverage N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Stability
100 /100
Stable
Beta 0.79x
Profitable years N/A
Rev. volatility N/A

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre CYBN
Online

Despre companie

Cybin Inc. (CYBN) is a biotechnology company specializing in the development of therapeutic therapies based on psychedelic compounds for the treatment of various mental disorders. The company focuses on developing medications that utilize psychedelic substances such as psilocybin to support the treatment of conditions like depression, anxiety disorders, and post-traumatic stress disorder. Cybin Inc. is engaged in clinical studies and research to provide new treatment options for patients suffering from mental illnesses. With the growing interest in alternative therapeutic approaches in the field of mental health, Cybin Inc. has the potential for sustained growth. Cybin Inc. (CYBN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies based on psychedelic compounds industry.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Eric So

Employees

50

Headquarters

Toronto

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.